{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016235","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2025-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.342597+00:00","generated_at":"2026-05-18T22:58:13.058706+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MAIA appoints HCC specialists to SAB; Phase 2 trial enrollment expected by year-end 2025","bullets":["Appointed Drs. Claudia Fulgenzi and David J. Pinato to SAB; both are HCC clinician-scientists.","Planning Phase 2 trial of ateganosine (THIO) plus checkpoint inhibitor in hepatocellular carcinoma (HCC).","Expects to begin enrolling HCC trial patients by end of 2025 upon obtaining regulatory approvals.","FDA granted Orphan Drug Designation for ateganosine in HCC in 2022, potentially 7-year market exclusivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016235","json":"https://secwatch.observer/filing/0001641172-25-016235.json","markdown":"https://secwatch.observer/filing/0001641172-25-016235.md","text":"https://secwatch.observer/filing/0001641172-25-016235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225016235/0001641172-25-016235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000164117225016235/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T22:58:13.058706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}